Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 02, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference

TORONTO, Ontario and CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of...
July 27, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference

TORONTO, Ontario and CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of...
July 08, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”

TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 08, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on...
June 27, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA

TORONTO, Ontario and CAMBRIDGE, MA, June 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
June 22, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Debt Amendment and Conversion

TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on...
June 22, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application

TORONTO, Ontario and CAMBRIDGE, Massachusetts , June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on...
June 22, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares

TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on...
May 17, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences presents at the 2022 Neuro4D International Conference

TORONTO, Ontario and CAMBRIDGE, MA, May 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
May 13, 2022 09:20 ET | Source: ProMIS Neurosciences Inc.

CORRECTION: ProMIS Neurosciences Announces First Quarter 2022 Results

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- There was an error at the end of the first paragraph. March 31, 2021 has been changed to March 31, 2022. There were no...
May 13, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces First Quarter 2022 Results

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on...